Oraya TherapyTM Stereotactic Radiotherapy for Wet AMD



British and Eire Association of Vitreoretinal Surgeons (BEAVRS)

November 5-6, 2015
Sheffield, United Kingdom

Retina Subspecialty Day, AAO 2015

Friday, November 13-14, 2015
Las Vegas, Nevada, USA

American Academy of Ophthalmology (AAO 2015)

November 14-17, 2015
Las Vegas, Nevada, USA
Visit Oraya Therapeutics Stand 2041




The Oraya Therapy is available in Germany, Switzerland and the United Kingdom. For more information:
In Germany, call 0800-283-2243
In Switzerland, call 41-61-4266000
In the United Kingdom, call 0800-690-6495
Find a treatment location >


Oraya Therapeutics Receives Professional Society Guidance on Use of Radiotherapy for Wet AMD in Germany. The joint opinion enables ophthalmologists to better identify patients who can benefit from Oraya Therapy. Press Release >


Leading Ophthalmologists

Leading Ophthalmologists Present Real World Clinical Outcomes on Oraya Therapy for Wet AMD at EURETINA 15th Congress. Non-invasive treatment shown to effectively maintain vision while reducing anti-VEGF injections. Press Release >


BBC Radio Sheffield – Interview: Consultant Ophthalmologist Chris Brand discusses treatment results for his wet AMD patients. Play >

Oraya Therapy Video

Age-Related Macular Degeneration (AMD) is a progressive disease that causes loss of central vision leading to blindness. It is the primary cause of vision loss for seniors in the industrialized world. While there is no cure for AMD, the Oraya Therapy™ for Wet AMD is an exciting new treatment.   More >


Founded in 2007, Oraya® Therapeutics, Inc. is a privately held company developing an innovative and non-invasive therapy designed to advance the treatment options for wet AMD.  More >


Physicians and patients require a new option and a new vision for the treatment of wet AMD. Oraya Therapy— intended as a one-time, non-invasive procedure—uses a low-voltage, stereotactic approach. It delivers precisely controlled X-rays confined to the diseased area of interest, sparing the surrounding structures of the eye.  More >


Published Articles
Stereotactic Radiotherapy for Neovascular Age-Related Macular Degeneration: Year 2 Results of the INTREPID Study

Published in Ophthalmology, January 2015.
Free Download >

© 2015 All rights reserved. Oraya Therapeutics, Inc. The IRay® is a CE-marked medical device. The IRay is not available for sale in the United States. For additional details, including safety and risk information, please see the ORAYA THERAPY section of this website. Oraya, Oraya Therapy, IRay and I-Guide are either trademarks or registered trademarks of Oraya Therapeutics, Inc. in the United States and other countries.